Cited by 1,546Hemoglobinopathies and Related DisordersBlood groups and transfusionMalaria Research and Control

Pain in Sickle Cell Disease: Rates and Risk Factors

Open access
Platt, Orah S., Thorington, Bruce D., Brambilla, Donald J., Milner, Paul F., Rosse, Wendell F., Vichinsky, Elliott, Kinney, Thomas R.·1991·New England Journal of Medicine

Abstract

BACKGROUND AND METHODS: Acute episodes of pain are the principal symptom of sickle cell disease, but little is known about the epidemiologic features of these episodes or risk factors for them, nor is it known whether patients with high rates of such episodes die prematurely. We prospectively studied the natural history of sickle cell disease in 3578 patients ranging from newborns to persons up to 66 years old who were followed at clinical centers across the United States. RESULTS: There were 12,290 episodes of pain in 18,356 patient-years. The average rate was 0.8 episode per patient-year in sickle cell anemia, 1.0 episode per patient-year in sickle beta 0-thalassemia, and 0.4 episode per patient-year in hemoglobin SC disease and sickle beta(+)-thalassemia. The rate varied widely within each of these four groups--e.g., 39 percent of patients with sickle cell anemia had no episodes of pain, and 1 percent had more than six episodes per year. The 5.2 percent of patients with 3 to 10 episodes per year had 32.9 percent of all episodes. Among patients with sickle cell anemia who were more than 20 years old, those with high rates of pain episodes tended to die earlier than those with low rates. High rates were associated with a high hematocrit and low fetal hemoglobin levels. alpha-Thalassemia had no effect on pain apart from its association with an increased hematocrit. CONCLUSIONS: The "pain rate" (episodes per year) is a measure of clinical severity and correlates with early death in patients with sickle cell anemia over the age of 20. Even when the fetal hemoglobin level is low, one can predict that small increments in the level may have an ameliorating effect on the pain rate and may ultimately improve survival. This outcome is particularly encouraging to investigators studying hydroxyurea and other treatments designed to increase the fetal hemoglobin level.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejm199107043250103

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Such levels of βh1-globin expression, if achieved at the fetal globin genes in vivo in human sickle cell anemia patients, would be sufficient to ameliorate the clinical course of their disease.

    “In fact, such levels, if achieved at the fetal globin genes in vivo in human sickle cell anemia patients would be sufficient to ameliorate the clinical course of their disease (see also below) (Noguchi et al., 1988; Platt et al., 1991).”

    From Reactivation of developmentally silenced globin genes by forced chromatin looping (2014) · cites this paper as Platt et al., 1991

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 25 · Cited by 1,546

Research works printed but not linked: 6

  1. [1]1. Konotey-Ahulu FID. The sickle cell diseases. Arch Intern Med 1974; 133:611-9.
  2. [6]6. Cnaan A, Ryan L. Survival analysis in natural history studies of disease. Stat Med 1989; 8:1255-68.
  3. [7]7. Dixon WJ, Brown MB, Engelman L, Jennrich RI, eds. BMDP statistical software manual. Vol. 2. Berkeley: University of California, 1990.
  4. [8]8. Baker RJ, Nelder JA. The GLIM system. Release 3. Oxford, England: Numerical Algorithms Group, 1978.
  5. [19]19. Lande WM, Andrews DL, Clark MR, et al. The incidence of painful crisis in homozygous sickle cell disease. Blood 1988; 72:2056-9.
  6. [26]26. Charache S, Dover GJ, Moyer MA, Moore JW. Hydroxyurea-induced augmenl l i i en a od nen mia. Blood 1987; 69:109-16.

Authors
Platt, O. S., Thorington, B. D., Brambilla, D. J., Milner, P. F., Rosse, W. F., Vichinsky, E., & Kinney, T. R.
Affiliations
  • Harvard University (US)
  • New England Research Institutes (US)
  • Augusta University (US)
  • Duke University (US)
Venue
New England Journal of Medicine
Published
1991-07-04
Volume
325
Issue
1
Pages
11-16
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2322074970
Cited by
1,546
References
25
Citations by year
2026: 33 · 2025: 36 · 2024: 35 · 2023: 48 · 2022: 48 · 2021: 59 · 2020: 61 · 2019: 59 · 2018: 59 · 2017: 72 · 2016: 84 · 2015: 78 · 2014: 86 · 2013: 58 · 2012: 50
FWCI
14.80
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Genetics › Hemoglobinopathies and Related Disorders
  • Health Sciences › Medicine › Hematology › Blood groups and transfusion
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
Keywords
sickle cell disease, pain episodes, sickle beta-thalassemia, hemoglobin SC disease, alpha-thalassemia, fetal hemoglobin, hematocrit, mortality, clinical severity, hydroxyurea, natural history (disease)
MeSH terms
Adolescent, Adult, Age Factors, Aged, Anemia, Sickle Cell, Child, Child, Preschool, Female, Fetal Hemoglobin, Hematocrit, Hemoglobin SC Disease, Humans, Infant, Infant, Newborn, Male, Middle Aged, Pain, Risk Factors, Thalassemia, United States, Incidence, Survival Rate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review